,neg,neu,pos,compound,headline,label
0,0.0,1.0,0.0,0.0,The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study,0
1,0.0,1.0,0.0,0.0,Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination,0
2,0.0,0.826,0.174,0.2732,Clonal dynamics of SARS-CoV-2-specific T cells in children and adults with COVID-19,1
3,0.091,0.909,0.0,-0.25,Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-months,-1
4,0.0,1.0,0.0,0.0,Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients,0
5,0.0,1.0,0.0,0.0,SARS‐CoV‐2 induced post‐translational protein modifications: A trigger for developing autoimmune diabetes?,0
6,0.293,0.707,0.0,-0.6597,Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks,-1
7,0.0,1.0,0.0,0.0,Gastrointestinal Symptoms in Children With SARS-CoV-2 or Multisystem Inflammatory Syndrome,0
8,0.148,0.638,0.215,0.4588,Risk factors of mortality among patients hospitalised with COVID-19 in a critical care or hospital care unit: analysis of the French national medicoadministrative database,1
9,0.0,0.897,0.103,0.128,SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies,1
10,0.0,1.0,0.0,0.0,Neuroinflammation in SARS-CoV2 infection: Pathogenesis and clinical manifestations,0
11,0.0,0.856,0.144,0.4019,"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron",1
12,0.0,1.0,0.0,0.0,Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection,0
13,0.0,1.0,0.0,0.0,"Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein",0
14,0.139,0.861,0.0,-0.2732,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",-1
15,0.0,1.0,0.0,0.0,Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron,0
16,0.0,1.0,0.0,0.0,To Mask or Not to Mask—Evaluation of Cognitive Performance in Children Wearing Face Masks during School Lessons (MasKids),0
17,0.139,0.73,0.131,-0.0258,"T-cell vaccines could top up immunity to COVID, as variants loom large",0
18,0.0,1.0,0.0,0.0,Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy,0
19,0.207,0.643,0.15,-0.2023,Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden,-1
20,0.134,0.722,0.144,0.0516,Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States,0
21,0.13,0.87,0.0,-0.2732,SARS-CoV-2 infection of the central nervous system in a 14-month-old child: A case report of a complete autopsy,-1
22,0.237,0.763,0.0,-0.4215,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,-1
23,0.0,1.0,0.0,0.0,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,0
24,0.0,1.0,0.0,0.0,Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum,0
25,0.0,0.743,0.257,0.4215,Interdependencies between cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination,1
26,0.178,0.822,0.0,-0.3818,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,-1
27,0.104,0.896,0.0,-0.2732,Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2),-1
28,0.0,1.0,0.0,0.0,"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination",0
29,0.0,1.0,0.0,0.0,Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant,0
30,0.0,1.0,0.0,0.0,Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants,0
31,0.124,0.795,0.082,-0.2525,HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung,-1
32,0.0,1.0,0.0,0.0,Eight unanswered questions about the COVID-19 pandemic,0
33,0.0,1.0,0.0,0.0,False-Positive Results in Rapid Antigen Tests for SARS-CoV-2,0
34,0.0,1.0,0.0,0.0,"Nowcasting (Short-Term Forecasting) of COVID-19 Hospitalizations Using Syndromic Healthcare Data, Sweden, 2020",0
35,0.167,0.833,0.0,-0.25,Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis,-1
36,0.0,1.0,0.0,0.0,Pathological sequelae of long-haul COVID,0
37,0.0,1.0,0.0,0.0,Omicron largely evades immunity from past infection or two vaccine doses,0
38,0.0,1.0,0.0,0.0,Adherence of SARS-CoV-2 delta variant to surgical mask and N95 respirators,0
39,0.0,1.0,0.0,0.0,"Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance",0
40,0.0,1.0,0.0,0.0,"Projected epidemiological consequences of the Omicron SARS-CoV-2 variant in England, December 2021 to April 2022",0
41,0.0,0.787,0.213,0.2263,EMA recommends Nuvaxovid for authorisation in the EU,1
42,0.076,0.855,0.069,-0.0534,"Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas",0
43,0.0,1.0,0.0,0.0,"Association of ABO blood group with COVID-19 severity, acute phase reactants and mortality",0
44,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - December 20, 2021",0
45,0.0,1.0,0.0,0.0,Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities,0
46,0.0,1.0,0.0,0.0,Omicron overpowers key COVID antibody treatments in early tests,0
47,0.0,1.0,0.0,0.0,Self-reported long COVID after two doses of a coronavirus (COVID-19) vaccine in the UK,0
48,0.0,0.694,0.306,0.5267,Prospective mapping of viral mutations that escape antibodies used to treat COVID-19,1
49,0.186,0.814,0.0,-0.4939,"Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron",-1
50,0.0,1.0,0.0,0.0,Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease,0
51,0.0,0.914,0.086,0.1531,Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naïve and subjects recovered from COVID-19,1
52,0.0,0.71,0.29,0.5423,Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant,1
53,0.198,0.589,0.213,-0.088,"Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta- analysis and GRADE assessment of cohort studies and RCTs",0
54,0.0,1.0,0.0,0.0,Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans,0
55,0.0,1.0,0.0,0.0,Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant,0
56,0.0,1.0,0.0,0.0,Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection,0
57,0.0,1.0,0.0,0.0,Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies,0
58,0.0,1.0,0.0,0.0,Direct Comparison of SARS Co-V-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOWTM) at a Community Testing Site During an Omicron Surge,0
59,0.0,0.884,0.116,0.2732,Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals,1
60,0.0,1.0,0.0,0.0,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 32,0
61,0.0,0.839,0.161,0.5334,T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals,1
62,0.0,1.0,0.0,0.0,"Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California",0
63,0.0,1.0,0.0,0.0,"Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval",0
64,0.0,0.576,0.424,0.5994,SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape,1
65,0.118,0.633,0.249,0.4404,RECOVERY Trial to investigate whether higher doses of dexamethasone deliver greater benefit for patients with severe COVID-19,1
66,0.0,1.0,0.0,0.0,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients,0
67,0.401,0.599,0.0,-0.6908,SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling,-1
68,0.0,1.0,0.0,0.0,Genomic Perspectives on the Emerging SARS-CoV-2 Omicron Variant,0
69,0.0,1.0,0.0,0.0,Association of Complement and MAPK Activation With SARS-CoV-2–Associated Myocardial Inflammation,0
70,0.0,1.0,0.0,0.0,Autoimmune Hemolytic Anemia After mRNA COVID Vaccine,0
71,0.0,1.0,0.0,0.0,What the Omicron wave is revealing about human immunity,0
72,0.157,0.73,0.112,-0.2023,Comprehensive Chemosensory Psychophysical Evaluation of Self-reported Gustatory Dysfunction in Patients With Long-term COVID-19 A Cross-sectional Study,-1
73,0.0,0.823,0.177,0.4215,COVID-19-Associated Hospitalizations Among Children Less Than 12 Years of Age in the United States,1
74,0.0,0.902,0.098,0.3818,Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) can resolve their persistent symptoms,1
75,0.0,0.847,0.153,0.4404,HKUMed-CU Medicine joint study finds that third dose of Comirnaty has better protection from COVID-19 variant Omicron,1
76,0.137,0.7,0.163,-0.0516,"The mental health crisis of expectant women in the UK: effects of the COVID-19 pandemic on prenatal mental health, antenatal attachment and social support",0
77,0.0,1.0,0.0,0.0,SARS-CoV-2 infection and persistence throughout the human body and brain,0
78,0.0,1.0,0.0,0.0,Detection and Interspecies Comparison of SARS-CoV-2 Delta Variant (AY.3) in Feces from a Domestic Cat and Human Samples,0
79,0.0,1.0,0.0,0.0,SARS-CoV-2 Spike protein activates TMEM16F-mediated platelet pro-coagulant activity,0
80,0.0,0.682,0.318,0.6808,"COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021",1
81,0.0,0.811,0.189,0.3612,"The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism",1
82,0.0,1.0,0.0,0.0,Computational screening of potential drugs against COVID-19 disease: the Neuropilin-1 receptor as molecular target,0
83,0.0,1.0,0.0,0.0,Global fine-scale changes in ambient NO2 during COVID-19 lockdowns,0
84,0.0,0.881,0.119,0.4019,"The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry.",1
85,0.128,0.872,0.0,-0.2263,Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2,-1
86,0.0,0.811,0.189,0.4215,Sex disparities in COVID-19 outcomes in the United States: Quantifying and contextualizing variation,1
87,0.0,1.0,0.0,0.0,Persistent SARS-2 infections contribute to long COVID-19,0
88,0.342,0.658,0.0,-0.3818,T cell apoptosis characterizes severe Covid-19 disease,-1
89,0.0,1.0,0.0,0.0,Wastewater-based epidemiology for SARS-CoV-2 surveillance in South Africa - Week 48 2021,0
90,0.0,0.907,0.093,0.1655,SARS-CoV-2 Omicron Spike Glycoprotein Receptor Binding Domain Exhibits Super-Binder Ability with ACE2 but not Convalescent Monoclonal Antibody,1
91,0.0,1.0,0.0,0.0,Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer,0
92,0.0,1.0,0.0,0.0,Alzheimer's‐like signaling in brains of COVID‐19 patients,0
93,0.0,1.0,0.0,0.0,Innate immunological pathways in COVID-19 pathogenesis,0
94,0.0,1.0,0.0,0.0,Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study,0
95,0.105,0.789,0.105,0.0,Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults,0
96,0.0,1.0,0.0,0.0,The puzzling mutational landscape of the SARS-2-variant Omicron,0
97,0.0,1.0,0.0,0.0,SARS-CoV-2 Omicron Variant AI-based Primers,0
98,0.0,1.0,0.0,0.0,Presence of SARS-CoV-2 Aerosol in Residences of Adults with COVID-19,0
99,0.0,1.0,0.0,0.0,Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19 Pandemic in Germany: Results From the DPV Registry,0
100,0.159,0.647,0.194,0.1531,High Rates of Rapid Antigen Test Positivity After 5 Days of Isolation for COVID-19,1
101,0.0,1.0,0.0,0.0,A National Strategy for the “New Normal” of Life With COVID,0
102,0.0,1.0,0.0,0.0,Mining long-COVID symptoms from Reddit: characterizing post-COVID syndrome from patient reports,0
103,0.0,1.0,0.0,0.0,Insights on the mutational landscape of the SARS-CoV-2 Omicron variant,0
104,0.0,0.876,0.124,0.4019,Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period,1
105,0.0,1.0,0.0,0.0,Cross reactivity of spike glycoprotein induced antibody against delta and omicron variants before and after third SARS-CoV-2 vaccine dose,0
106,0.0,1.0,0.0,0.0,SARS-CoV-2 Omicron VOC Transmission in Danish Households,0
107,0.0,0.685,0.315,0.5574,Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection,1
108,0.0,1.0,0.0,0.0,Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar,0
109,0.0,1.0,0.0,0.0,SARS-CoV-2 infections in children: understanding diverse outcomes,0
110,0.077,0.923,0.0,-0.3818,"Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery",-1
111,0.0,1.0,0.0,0.0,NIH Funding of COVID-19 Research in 2020: a Cross Sectional Study,0
112,0.0,1.0,0.0,0.0,What does Omicron mean for future COVID-19 vaccinations?,0
113,0.0,0.828,0.172,0.4019,"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern",1
114,0.122,0.878,0.0,-0.3612,Systematic review of cardiac adverse effects in children and young people un-der 18 years of age after SARS-CoV-2 vaccination,-1
115,0.0,0.826,0.174,0.2732,Endothelin-1 is Increased in the Plasma of Patients Hospitalized with Covid-19,1
116,0.0,1.0,0.0,0.0,Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases,0
117,0.258,0.565,0.177,-0.25,Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2,-1
118,0.0,0.898,0.102,0.3612,"Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity",1
119,0.0,1.0,0.0,0.0,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",0
120,0.0,0.739,0.261,0.5574,A single-cell atlas reveals shared and distinct immune responses and metabolism during SARS-CoV-2 and HIV-1 infections,1
121,0.0,1.0,0.0,0.0,Mucociliary Transport Deficiency and Disease Progression in Syrian Hamsters with SARS-CoV-2 Infection,0
122,0.0,1.0,0.0,0.0,Investigating the impacts of COVID-19 among LGBTQ2S youth experiencing homelessness,0
123,0.173,0.827,0.0,-0.3182,The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste,-1
124,0.213,0.787,0.0,-0.4019,Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness,-1
125,0.0,0.714,0.286,0.34,SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting,1
126,0.0,0.879,0.121,0.296,"Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response",1
127,0.0,1.0,0.0,0.0,Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike,0
128,0.0,1.0,0.0,0.0,Molnupiravir to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19,0
129,0.276,0.588,0.135,-0.34,CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients,-1
130,0.0,0.909,0.091,0.0772,Iota-Carrageenan Prevents the Replication of SARS-CoV-2 in a Human Respiratory Epithelium Cell Line in vitro,0
131,0.0,1.0,0.0,0.0,COVID-19 mRNA vaccine may trigger subacute thyroiditis,0
132,0.0,1.0,0.0,0.0,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination,0
133,0.0,1.0,0.0,0.0,"Surveillance of Rodent Pests for SARS-CoV-2 and Other Coronaviruses, Hong Kong",0
134,0.0,1.0,0.0,0.0,How does Omicron spread so fast? A high viral load isn’t the answer,0
135,0.0,1.0,0.0,0.0,Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients,0
136,0.0,1.0,0.0,0.0,Epidemiological update: Omicron variant of concern (VOC) – data as of 10 December 2021 (12:00),0
137,0.0,0.92,0.08,0.1027,"Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave",1
138,0.0,1.0,0.0,0.0,"Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa",0
139,0.0,0.833,0.167,0.34,SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron,1
140,0.0,1.0,0.0,0.0,Menstruation and covid-19 vaccination,0
141,0.0,1.0,0.0,0.0,Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron,0
142,0.0,0.825,0.175,0.1779,Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses,1
143,0.0,0.856,0.144,0.4019,From Deer-to-Deer: SARS-CoV-2 is efficiently transmitted and presents broad tissue tropism and replication sites in white-tailed deer,1
144,0.102,0.749,0.15,0.2263,"Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta",1
145,0.0,1.0,0.0,0.0,The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders,0
146,0.0,1.0,0.0,0.0,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,0
147,0.0,1.0,0.0,0.0,Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection,0
148,0.0,1.0,0.0,0.0,Seeing Is Believing: COVID-19 Vaccination Leads to Less Pneumonia at Chest CT,0
149,0.0,1.0,0.0,0.0,Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift,0
150,0.0,1.0,0.0,0.0,"After Omicron, some scientists foresee ‘a period of quiet’",0
151,0.0,1.0,0.0,0.0,Resistance of SARS-CoV-2 Omicron Variant to Convalescent and CoronaVac Vaccine Plasma,0
152,0.0,1.0,0.0,0.0,Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine,0
153,0.0,0.87,0.13,0.2732,Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults,1
154,0.0,1.0,0.0,0.0,Trypsin enhances SARS-CoV-2 infection by facilitating viral entry,0
155,0.271,0.729,0.0,-0.3818,Interferon system deficiencies exacerbating severe pandemic virus infections,-1
156,0.0,1.0,0.0,0.0,Systematic review and meta-analysis of covid-19 vaccine placebo groups,0
157,0.0,1.0,0.0,0.0,Assessing the effect of beard hair lengths on face masks used as personal protective equipment during the COVID-19 pandemic,0
158,0.0,0.833,0.167,0.3818,Mutations in RBD of SARS-CoV-2 Omicron variant result stronger binding to human ACE2 protein,1
159,0.0,1.0,0.0,0.0,Antibody-dependent enhancement of coronavirus,0
160,0.0,1.0,0.0,0.0,SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response,0
161,0.0,1.0,0.0,0.0,SARS-CoV-2 Variants of Concern Infect the Respiratory Tract and Induce Inflammatory Response in Wild-Type Laboratory Mice,0
162,0.0,1.0,0.0,0.0,Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes,0
163,0.0,1.0,0.0,0.0,Prevalence of Salivary IgA Reacting with SARS-CoV-2 among Japanese People Unexposed to the Virus,0
164,0.0,1.0,0.0,0.0,Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19,0
165,0.0,1.0,0.0,0.0,"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact",0
166,0.0,1.0,0.0,0.0,SARS-CoV-2 infection results in lasting and systemic perturbations post recovery,0
167,0.052,0.948,0.0,-0.0258,Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants,0
168,0.281,0.719,0.0,-0.5994,SARS-CoV-2 Infection of Microglia Elicits Pro-inflammatory Activation and Apoptotic Cell Death,-1
169,0.0,0.737,0.263,0.6908,Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England,1
170,0.0,1.0,0.0,0.0,Neutralization profile of Omicron variant convalescent individuals,0
171,0.223,0.777,0.0,-0.3182,Human genetic and immunological determinants of critical COVID-19 pneumonia,-1
172,0.157,0.843,0.0,-0.4215,Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy,-1
173,0.0,0.769,0.231,0.5859,Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant,1
174,0.228,0.67,0.103,-0.4215,Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells,-1
175,0.0,0.706,0.294,0.3612,Vaxzevria significantly boosted antibody levels against Omicron,1
176,0.0,1.0,0.0,0.0,GlycoGrip: Cell Surface-Inspired Universal Sensor for Betacoronaviruses,0
177,0.0,1.0,0.0,0.0,Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals,0
178,0.0,1.0,0.0,0.0,Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa,0
179,0.118,0.882,0.0,-0.0516,High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron,0
180,0.0,1.0,0.0,0.0,Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose,0
181,0.0,1.0,0.0,0.0,Indirect effects of the covid-19 pandemic on childhood infection in England: population based observational study,0
182,0.0,0.8,0.2,0.3612,Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy,1
183,0.0,0.813,0.187,0.4144,Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis,1
184,0.0,1.0,0.0,0.0,Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming,0
185,0.0,1.0,0.0,0.0,Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study,0
186,0.0,1.0,0.0,0.0,Platelets mediate inflammatory monocyte activation by SARS-CoV-2 Spike protein,0
187,0.0,0.833,0.167,0.296,Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses,1
188,0.246,0.754,0.0,-0.5994,Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates,-1
189,0.0,1.0,0.0,0.0,Real-time pandemic surveillance using hospital admissions and mobility data,0
190,0.0,1.0,0.0,0.0,Acquired neutralizing breadth against SARS-CoV-2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the vaccine efficacy,0
191,0.174,0.826,0.0,-0.2732,Toward Accurate Spatiotemporal COVID-19 Risk Scores Using High-Resolution Real-World Mobility Data,-1
192,0.0,0.833,0.167,0.5574,"Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19",1
193,0.192,0.808,0.0,-0.2263,Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro,-1
194,0.0,0.861,0.139,0.2732,Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response,1
195,0.0,1.0,0.0,0.0,Resistance Conferring Mutations in Sars-CoV-2 Delta Following Sotrovimab Infusion,0
196,0.059,0.941,0.0,-0.0516,Transmission of SARS-CoV-2 (Variant Delta) from Pet Hamsters to Humans and Onward Human Propagation of the Adapted Strain: A Case Study,0
197,0.0,1.0,0.0,0.0,Sequelae in Adults at 6 Months After COVID-19 Infection,0
198,0.0,1.0,0.0,0.0,"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial",0
199,0.0,0.84,0.16,0.2732,Sudden rise of more transmissible form of Omicron catches scientists by surprise,1
200,0.0,1.0,0.0,0.0,Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant,0
201,0.0,1.0,0.0,0.0,Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min,0
202,0.0,1.0,0.0,0.0,Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK,0
203,0.0,1.0,0.0,0.0,"Serial Intervals and Household Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021",0
204,0.401,0.599,0.0,-0.7717,Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants,-1
205,0.0,1.0,0.0,0.0,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience,0
206,0.0,1.0,0.0,0.0,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,0
207,0.0,0.556,0.444,0.802,Symptoms COVID 19 Positive Vapers Compared to COVID 19 Positive Non-vapers,1
208,0.141,0.859,0.0,-0.3182,Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain,-1
209,0.0,1.0,0.0,0.0,Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein,0
210,0.245,0.755,0.0,-0.3818,Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture,-1
211,0.271,0.729,0.0,-0.3818,Outcomes of SARS-CoV-2–Positive Youths Tested in Emergency Departments,-1
212,0.0,0.838,0.162,0.4019,OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients,1
213,0.0,0.733,0.267,0.4588,Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses,1
214,0.0,1.0,0.0,0.0,Relationship between blood type and outcomes following COVID-19 infection,0
215,0.123,0.877,0.0,-0.2732,Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C,-1
216,0.0,1.0,0.0,0.0,SARS-CoV-2 Omicron variant replication in human respiratory tract ex vivo,0
217,0.0,1.0,0.0,0.0,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination,0
218,0.0,1.0,0.0,0.0,Impact of COVID-19 on new-onset type 1 diabetes mellitus - A one-year prospective study,0
219,0.0,1.0,0.0,0.0,High prevalence of olfactory disorders 18 months after contracting COVID-19,0
220,0.139,0.861,0.0,-0.2732,Severity of COVID-19 reinfection and associated risk factors: findings of a cross-sectional study in Bangladesh,-1
221,0.0,0.887,0.113,0.4215,"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial",1
222,0.178,0.822,0.0,-0.3818,CDC Releases Emergency Guidance for Healthcare Facilities to Prepare for Potential Omicron Surge,-1
223,0.344,0.656,0.0,-0.2732,Nervous system consequences of COVID-19,-1
224,0.0,1.0,0.0,0.0,Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant,0
225,0.0,1.0,0.0,0.0,SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study,0
226,0.0,1.0,0.0,0.0,SARS-CoV-2-specific T cells in infection and vaccination,0
227,0.0,1.0,0.0,0.0,"SAGE 98 minutes: Coronavirus (COVID-19) response, 7 December 2021",0
228,0.0,1.0,0.0,0.0,Rapid Diagnostic Testing for SARS-CoV-2,0
229,0.0,1.0,0.0,0.0,Genomic surveillance reveals the emergence of SARS-CoV-2 Lineage A from Islamabad Pakistan,0
230,0.0,1.0,0.0,0.0,SARS-CoV-2 Viral Genes Compromise Survival and Functions of Human Pluripotent Stem Cell-derived Cardiomyocytes via Reducing Cellular ATP Level,0
231,0.0,1.0,0.0,0.0,The COG-UK/Mutation Explorer (COG-UK/ME) provides information and structural context on mutations and associated variants in the genes encoding SARS-COV-2.,0
232,0.0,1.0,0.0,0.0,Differences in environmental stability among SARS-CoV-2 variants of concern: Omicron has higher stability,0
233,0.0,1.0,0.0,0.0,SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interaction,0
234,0.0,1.0,0.0,0.0,RECOVERY Trial launches in South Africa,0
235,0.0,1.0,0.0,0.0,Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients,0
236,0.0,1.0,0.0,0.0,Direct Comparison of SARS Co-V-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOW™) at a Community Testing Site During an Omicron Surge,0
237,0.236,0.764,0.0,-0.5267,SARS-CoV-2 placentitis associated with B.1.617.2 (Delta) variant and fetal distress or demise,-1
238,0.0,0.829,0.171,0.2144,"SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium",1
239,0.0,1.0,0.0,0.0,"Coronavirus Disease Case Definitions, Diagnostic Testing Criteria, and Surveillance in 25 Countries with Highest Reported Case Counts",0
240,0.0,1.0,0.0,0.0,Individual and Work Factors Associated with Psychosocial Health of Registered Nurses During the Covid-19 Pandemic,0
241,0.187,0.813,0.0,-0.3182,SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment,-1
242,0.0,0.813,0.187,0.3182,EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count,1
243,0.208,0.792,0.0,-0.2732,Early Computational Detection of Potential High Risk SARS-CoV-2 Variants,-1
244,0.0,1.0,0.0,0.0,Modelling the potential consequences of the Omicron SARS-CoV-2 variant in England,0
245,0.0,0.576,0.424,0.7964,Analyzing natural herd immunity media discourse in the United Kingdom and the United States,1
246,0.0,0.861,0.139,0.2732,Effect of Increased Alcohol Consumption During COVID‐19 Pandemic on Alcohol‐related Liver Disease: A Modeling Study,1
247,0.119,0.635,0.246,0.3818,High-cited favorable studies for COVID-19 treatments ineffective in large trials,1
248,0.0,1.0,0.0,0.0,SARS-CoV-2 spike conformation determines plasma neutralizing activity,0
249,0.0,1.0,0.0,0.0,ACE2 binding is an ancestral and evolvable trait of sarbecoviruses,0
250,0.0,1.0,0.0,0.0,Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19,0
251,0.0,1.0,0.0,0.0,Structural basis for antibody resistance to SARS-CoV-2 omicron variant,0
252,0.0,1.0,0.0,0.0,Disrupted Peyer’s patch microanatomy in COVID-19 including germinal centre atrophy independent of local virus,0
253,0.208,0.792,0.0,-0.2732,Report 50: Hospitalisation risk for Omicron cases in England,-1
254,0.0,1.0,0.0,0.0,SARS-CoV-2 infection in free-ranging white-tailed deer,0
255,0.098,0.795,0.106,0.0516,Outcomes from birth to 6 months of publicly insured infants born to mothers with severe acute respiratory syndrome coronavirus 2 infection in the United States,0
256,0.427,0.573,0.0,-0.6908,Loss of Y in leukocytes as a risk factor for critical COVID-19 in men,-1
257,0.0,0.854,0.146,0.34,Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen,1
258,0.0,1.0,0.0,0.0,Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series,0
259,0.265,0.544,0.19,-0.2732,The pandemic’s true death toll: millions more than official counts,-1
260,0.211,0.789,0.0,-0.4939,Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California,-1
261,0.0,1.0,0.0,0.0,"SARS-CoV-2 Omicron Variant: ACE2 Binding, Cryo-EM Structure of Spike Protein-ACE2 Complex and Antibody Evasion",0
262,0.0,1.0,0.0,0.0,Hospital admission for COVID-19 pneumonitis – long-term impairment in quality of life and lung function,0
263,0.286,0.714,0.0,-0.7017,SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19,-1
264,0.0,1.0,0.0,0.0,Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection,0
265,0.0,1.0,0.0,0.0,Updated projections for COVID-19 omicron wave in Florida,0
266,0.153,0.847,0.0,-0.2023,Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate,-1
267,0.0,0.827,0.173,0.3182,Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2,1
268,0.0,1.0,0.0,0.0,Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers,0
269,0.0,0.735,0.265,0.6597,Reduced Antibody and Cellular Immune Responses Following Dual COVID-19 Vaccination Within Infection-Naïve Residents of Long-Term Care Facilities,1
270,0.0,1.0,0.0,0.0,Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection,0
271,0.0,0.872,0.128,0.296,"Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination",1
272,0.0,1.0,0.0,0.0,"Now, an Omicron variant, BA.2, accounts for almost half of all Danish Omicron-cases",0
273,0.0,1.0,0.0,0.0,Transition of antibody titers after the SARS-CoV-2 mRNA vaccine in Japanese healthcare workers,0
274,0.0,1.0,0.0,0.0,Symptoms persisting after hospitalization for COVID-19: 12 months interim results of the COFLOW study,0
275,0.0,1.0,0.0,0.0,Lung abnormalities found in long COVID patients with breathlessness,0
276,0.0,1.0,0.0,0.0,Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies,0
277,0.0,1.0,0.0,0.0,SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 35,0
278,0.0,1.0,0.0,0.0,Rapid vigilance and episodic memory decrements in COVID-19 survivors,0
279,0.0,0.672,0.328,0.4404,"SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion",1
280,0.0,0.8,0.2,0.3612,Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third booster dose of vaccination,1
281,0.052,0.948,0.0,-0.0516,Omicron strain spreads with the doubling time of 3.2-3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant,0
282,0.0,1.0,0.0,0.0,Gasdermin-D activation by SARS-CoV-2 trigger NET and mediate COVID-19 immunopathology,0
283,0.0,1.0,0.0,0.0,"Amplification Artifact in SARS-CoV-2 Omicron Sequences Carrying P681R Mutation, New York, USA",0
284,0.0,0.877,0.123,0.2732,"Coinfection of SARS-CoV-2 and Influenza A virus increased disease severity, impaired neutralizing antibody, and CD4+ T cell responses",1
285,0.0,1.0,0.0,0.0,Does Covid-19 in children have a milder course than Influenza?,0
286,0.0,1.0,0.0,0.0,Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up.,0
287,0.0,1.0,0.0,0.0,Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2,0
288,0.0,1.0,0.0,0.0,Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants,0
289,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - January 03, 2022",0
290,0.0,0.777,0.223,0.5106,Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant,1
291,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - December 27, 2021",0
292,0.244,0.756,0.0,-0.4404,Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants,-1
293,0.0,1.0,0.0,0.0,Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes,0
294,0.0,1.0,0.0,0.0,Comparative evaluation of the sensitivities of SARSCoV-2 antigen rapid tests,0
295,0.0,1.0,0.0,0.0,China’s zero-COVID strategy: what happens next?,0
296,0.0,0.792,0.208,0.2732,Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time,1
297,0.318,0.682,0.0,-0.4215,NK cell dysfunction in patients with COVID-19,-1
298,0.0,1.0,0.0,0.0,Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents,0
299,0.0,0.804,0.196,0.296,Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection,1
300,0.0,0.631,0.369,0.4767,"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge",1
301,0.0,0.912,0.088,0.09,Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity,0
302,0.309,0.691,0.0,-0.7003,Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels,-1
303,0.0,0.565,0.435,0.6597,Face mask fit modifications that improve source control performance,1
304,0.0,0.825,0.175,0.5574,SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction,1
305,0.0,0.714,0.286,0.4939,Estimating the strength of selection for new SARS-CoV-2 variants,1
306,0.0,0.682,0.318,0.4215,Novavax COVID-19 vaccine Nuvaxovid approved by MHRA,1
307,0.0,1.0,0.0,0.0,The Investigation of Pulmonary Abnormalities using Hyperpolarised Xenon Magnetic Resonance Imaging in Patients with Long-COVID,0
308,0.0,0.753,0.247,0.5574,Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study,1
309,0.0,0.909,0.091,0.296,An intranasal lentiviral booster broadens immune recognition of SARS-CoV-2 variants and reinforces the waning mRNA vaccine-induced immunity that it targets to lung mucosa,1
310,0.0,0.735,0.265,0.2023,Universal Coronavirus Vaccines — An Urgent Need,1
311,0.331,0.552,0.116,-0.5994,Increased risk of hospitalisation and death with the delta variant in the USA,-1
312,0.0,0.67,0.33,0.7096,Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants,1
313,0.169,0.649,0.182,0.0516,Efficient Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from Exhaled Breath,0
314,0.0,0.833,0.167,0.4215,Incidence of COVID-19 reinfection: an analysis of outpatient-based data in the United States of America,1
315,0.0,1.0,0.0,0.0,"SARS-CoV-2 B.1.619 and B.1.620 Lineages, South Korea, 2021",0
316,0.149,0.851,0.0,-0.2732,A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19,-1
317,0.0,1.0,0.0,0.0,NRP1 and furin as putative mediators of SARS-CoV-2 entry into human brain cells,0
318,0.0,0.649,0.351,0.6597,Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant,1
319,0.0,0.805,0.195,0.4404,The First 2 Years of COVID-19 Lessons to Improve Preparedness for the Next Pandemic,1
320,0.0,1.0,0.0,0.0,Antigenic determinants of SARS-CoV-2-specific CD4+ T cell lines reveals M protein-driven dysregulation of interferon signaling,0
321,0.0,0.838,0.162,0.4019,RNA Sequencing in COVID-19 patients identifies neutrophil activation biomarkers as a promising diagnostic platform for infections,1
322,0.156,0.844,0.0,-0.2584,"High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells",-1
323,0.0,1.0,0.0,0.0,"Plant-based diets, pescatarian diets and COVID-19 severity: a population-based case–control study in six countries",0
324,0.0,0.813,0.187,0.4404,In silico analysis of predicted differential MHC binding and CD8+ T-cell immune escape of SARS-CoV-2 B.1.1.529 variant mutant epitopes,1
325,0.194,0.806,0.0,-0.34,SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes,-1
326,0.0,1.0,0.0,0.0,Neurotoxic Amyloidogenic Peptides in the Proteome of SARS-COV2: Potential Implications for Neurological Symptoms in COVID-19,0
327,0.0,1.0,0.0,0.0,Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals,0
328,0.0,0.748,0.252,0.4019,Omicron's molecular structure could help explain its global takeover,1
329,0.062,0.938,0.0,-0.1027,Front Cover: MPI8 is Potent against SARS‐CoV‐2 by Inhibiting Dually and Selectively the SARS‐CoV‐2 Main Protease and the Host Cathepsin L (ChemMedChem 1/2022),-1
330,0.0,1.0,0.0,0.0,Myocarditis after vaccination against covid-19,0
331,0.0,1.0,0.0,0.0,The association of statins use with survival of patients with COVID-19,0
332,0.0,1.0,0.0,0.0,Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography,0
333,0.0,1.0,0.0,0.0,The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters,0
334,0.0,1.0,0.0,0.0,Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection,0
335,0.167,0.833,0.0,-0.3818,Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine,-1
336,0.0,1.0,0.0,0.0,Enhanced apoptosis as a possible mechanism to self-limit SARS-CoV-2 replication in porcine primary respiratory epithelial cells in contrast to human cells,0
337,0.094,0.906,0.0,-0.4939,COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN). Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. First report on a double-blind placebo-controlled phase II clinical trial.,-1
338,0.0,1.0,0.0,0.0,COVID mortality in India: National survey data and health facility deaths,0
339,0.0,1.0,0.0,0.0,"Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the context of the ongoing Delta VOC transmission in the EU/EEA, 18th update",0
340,0.0,1.0,0.0,0.0,Early lab studies hint Omicron may be milder. But most scientists reserve judgment,0
341,0.0,0.759,0.241,0.4215,Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort,1
342,0.115,0.885,0.0,-0.296,"SARS-CoV-2 Omicron variant, lineage BA.1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant.",-1
343,0.0,1.0,0.0,0.0,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",0
344,0.0,0.87,0.13,0.2732,"Stochastic social behavior coupled to COVID-19 dynamics leads to waves, plateaus, and an endemic state",1
345,0.0,1.0,0.0,0.0,SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids,0
346,0.0,0.811,0.189,0.2732,Increased personal protective equipment litter as a result of COVID-19 measures,1
347,0.123,0.877,0.0,-0.2732,Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study,-1
348,0.249,0.635,0.116,-0.3612,Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses,-1
349,0.0,1.0,0.0,0.0,Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant,0
350,0.118,0.882,0.0,-0.25,Persistent symptoms following SARS-CoV-2 infection among children and young people: a meta-analysis of controlled and uncontrolled studies,-1
351,0.0,1.0,0.0,0.0,Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study,0
352,0.189,0.811,0.0,-0.2732,Why Parents Still Hesitate to Vaccinate Their Children Against COVID-19,-1
353,0.0,1.0,0.0,0.0,"Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021",0
354,0.0,1.0,0.0,0.0,Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae,0
355,0.13,0.87,0.0,-0.2732,Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years,-1
356,0.0,1.0,0.0,0.0,Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England,0
357,0.16,0.84,0.0,-0.2732,Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort,-1
358,0.0,1.0,0.0,0.0,Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals,0
359,0.0,1.0,0.0,0.0,Measurement of SARS-CoV-2 antigens in plasma of pediatric patients with acute COVID-19 or MIS-C using an ultrasensitive and quantitative immunoassay,0
360,0.115,0.885,0.0,-0.0772,Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics,0
361,0.0,1.0,0.0,0.0,Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms,0
362,0.0,1.0,0.0,0.0,Protection by 4th dose of BNT162b2 against Omicron in Israel,0
363,0.0,0.823,0.177,0.4215,"Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021",1
364,0.0,1.0,0.0,0.0,High-dose budesonide for early COVID-19,0
365,0.0,0.786,0.214,0.7184,"Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021",1
366,0.0,0.824,0.176,0.4576,Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention,1
367,0.0,1.0,0.0,0.0,Some reduction in hospitalisation for Omicron v Delta in England: early analysis,0
368,0.0,1.0,0.0,0.0,"Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021",0
369,0.0,0.663,0.337,0.6808,Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico,1
370,0.0,0.82,0.18,0.296,Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection,1
371,0.427,0.573,0.0,-0.802,Extubation Failure in Critically Ill COVID-19 Patients: Risk Factors and Impact on In-Hospital Mortality,-1
372,0.0,1.0,0.0,0.0,Inhalation Formulation Dosage of PVP Iodine for Respiratory Infections Early-Stage Treatment,0
373,0.0,0.797,0.203,0.4215,Lineage replacement and evolution captured by the United Kingdom Covid Infection Survey,1
374,0.0,1.0,0.0,0.0,mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern,0
375,0.189,0.559,0.252,0.2263,Test to release from isolation after testing positive for SARS-CoV-2,1
376,0.165,0.63,0.205,0.128,"The benefits, costs and feasibility of a low incidence COVID-19 strategy",1
377,0.0,0.811,0.189,0.4215,"COVID-19 Vaccination Coverage, Behaviors, and Intentions among Adults with Previous Diagnosis, United States",1
378,0.181,0.819,0.0,-0.4767,Impact of Delta Variant and Vaccination on SARS-CoV-2 Secondary Attack Rate Among Household Close Contacts,-1
379,0.0,1.0,0.0,0.0,"Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection In Vitro, despite Eliciting a Prolonged Antiviral Response",0
380,0.0,1.0,0.0,0.0,Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria,0
381,0.0,1.0,0.0,0.0,Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals,0
382,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - January 10, 2022",0
383,0.0,0.857,0.143,0.3612,"""I feel like my body is broken"": Exploring the experiences of people living with long COVID",1
384,0.0,1.0,0.0,0.0,SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study,0
385,0.0,0.714,0.286,0.4939,A proteomic survival predictor for COVID-19 patients in intensive care,1
386,0.0,0.792,0.208,0.5423,"Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial",1
387,0.0,0.879,0.121,0.296,Antibody-Dependent Enhancement of SARS-CoV-2 Infection of Human Immune Cells: In Vitro Assessment Provides Insight in COVID-19 Pathogenesis,1
388,0.0,0.769,0.231,0.5423,Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence,1
389,0.0,0.703,0.297,0.6705,"RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice",1
390,0.0,1.0,0.0,0.0,Effect of co-infection with intestinal parasites on COVID-19 severity: A prospective observational cohort study,0
391,0.226,0.522,0.252,0.0772,Is Methylprednisolone Better than Dexamethasone for Severe COVID-19?,0
392,0.0,0.905,0.095,0.3182,SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays,1
393,0.186,0.69,0.124,-0.2263,CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population,-1
394,0.298,0.702,0.0,-0.5267,Metabolic Syndrome and Acute Respiratory Distress Syndrome in COVID-19,-1
395,0.0,1.0,0.0,0.0,SARS-CoV-2 spreads through cell-to-cell transmission,0
396,0.0,1.0,0.0,0.0,Indirect protection of children from SARS-CoV-2 infection through parental vaccination,0
397,0.0,1.0,0.0,0.0,Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV-2: a report from the National COVID Cohort Collaborative (N3C),0
398,0.0,1.0,0.0,0.0,Vasculopathy in COVID-19,0
399,0.0,0.71,0.29,0.6486,Dynamics of anti-Spike IgG antibody level after full BNT162b2 COVID-19 vaccination in health care workers,1
400,0.0,1.0,0.0,0.0,Attenuated replication and pathogenesis of SARS-CoV-2 B.1.1.529 Omicron,0
401,0.0,1.0,0.0,0.0,Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave,0
402,0.0,0.867,0.133,0.3182,BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine,1
403,0.0,0.696,0.304,0.5859,SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans,1
404,0.469,0.531,0.0,-0.6486,Post-acute neurological consequences of COVID-19: an unequal burden,-1
405,0.308,0.564,0.128,-0.5423,The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies,-1
406,0.0,1.0,0.0,0.0,COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism,0
407,0.0,0.769,0.231,0.34,SARS-CoV-2 Quantum Sensor Based on Nitrogen-Vacancy Centers in Diamond,1
408,0.0,1.0,0.0,0.0,"Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test",0
409,0.0,0.842,0.158,0.4939,Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel,1
410,0.0,0.782,0.218,0.4404,A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally-infected and vaccinated subjects.,1
411,0.187,0.739,0.074,-0.4939,"Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December 2021",-1
412,0.0,1.0,0.0,0.0,Using correlates to accelerate vaccinology,0
413,0.0,1.0,0.0,0.0,Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2,0
414,0.14,0.86,0.0,-0.3818,Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients,-1
415,0.0,1.0,0.0,0.0,Mapping the antigenic diversification of SARS-CoV-2,0
416,0.157,0.843,0.0,-0.4215,The Sexual Long COVID (SLC): Erectile Dysfunction as a Biomarker of Systemic Complications for COVID-19 Long Haulers,-1
417,0.26,0.659,0.081,-0.5574,"APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study",-1
418,0.0,1.0,0.0,0.0,Impact of close interpersonal contact on COVID-19 incidence: Evidence from 1 year of mobile device data,0
419,0.0,0.872,0.128,0.3612,Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients,1
420,0.0,0.784,0.216,0.5106,Systemic infection of SARS-CoV-2 in free ranging Leopard (Panthera pardus fusca) in India,1
421,0.0,0.8,0.2,0.1901,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization,1
422,0.0,0.743,0.257,0.4215,Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection,1
423,0.0,1.0,0.0,0.0,Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial,0
424,0.0,1.0,0.0,0.0,Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports,0
425,0.0,0.914,0.086,0.1531,SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern,1
426,0.0,1.0,0.0,0.0,Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron),0
427,0.141,0.859,0.0,-0.4215,Effect of Full Vaccination and Post-covid Olfactory Dysfunction in Recovered Covid-19 Patient. A Retrospective Longitudinal Study With Propensity Matching.,-1
428,0.0,0.8,0.2,0.3612,Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine,1
429,0.0,0.65,0.35,0.5106,Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection,1
430,0.126,0.874,0.0,-0.3182,"Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants",-1
431,0.0,0.811,0.189,0.2732,Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022,1
432,0.0,1.0,0.0,0.0,Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents,0
433,0.0,0.828,0.172,0.4019,"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.",1
434,0.0,1.0,0.0,0.0,mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant,0
435,0.0,1.0,0.0,0.0,"Discovery Health, South Africa’s largest private health insurance administrator, releases at-scale, real-world analysis of Omicron outbreak based on 211 000 COVID-19 test results in South Africa, including collaboration with the South Africa",0
436,0.431,0.569,0.0,-0.7227,Omicron spreads but severe cases remain low in South Africa,-1
437,0.279,0.721,0.0,-0.4767,Facebook versus The BMJ: when fact checking goes wrong,-1
438,0.0,1.0,0.0,0.0,Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic,0
439,0.0,1.0,0.0,0.0,Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina,0
440,0.324,0.552,0.124,-0.4404,Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19,-1
441,0.0,1.0,0.0,0.0,Long-Term Air Pollution Exposure and COVID-19 Mortality: A Patient-Level Analysis from New York City,0
442,0.0,0.558,0.442,0.8519,Face mask fit hacks: Improving the fit of KN95 masks and surgical masks with fit alteration techniques,1
443,0.0,1.0,0.0,0.0,Saliva swabs are the preferred sample for Omicron detection,0
444,0.0,1.0,0.0,0.0,Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?,0
445,0.0,1.0,0.0,0.0,Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins,0
446,0.0,1.0,0.0,0.0,Social contact patterns and implications for infectious disease transmission – a systematic review and meta-analysis of contact surveys,0
447,0.0,1.0,0.0,0.0,A National Strategy for COVID-19 Medical Countermeasures Vaccines and Therapeutics,0
448,0.217,0.783,0.0,-0.5719,"Risk of Hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany",-1
449,0.0,1.0,0.0,0.0,"Covid-19 vaccines, immunity, and boosters",0
450,0.0,0.811,0.189,0.2732,Short-term Projections based on Early Omicron Variant Dynamics in England,1
451,0.0,0.667,0.333,0.7184,Treatment Benefit Index to Identify Patients With COVID-19 Who May Benefit From Convalescent Plasma,1
452,0.206,0.794,0.0,-0.6597,Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.,-1
453,0.0,1.0,0.0,0.0,Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2,0
454,0.0,0.877,0.123,0.4215,Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry,1
455,0.0,1.0,0.0,0.0,Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis,0
456,0.0,1.0,0.0,0.0,COVID-19 will continue but the end of the pandemic is near,0
457,0.351,0.649,0.0,-0.6597,Predicting Depression and Anxiety Among Adults With Disabilities During the COVID-19 Pandemic,-1
458,0.0,1.0,0.0,0.0,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",0
459,0.11,0.89,0.0,-0.2732,Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients,-1
460,0.0,1.0,0.0,0.0,Epidemiological update: Omicron variant of concern (VOC) – data as of 8 December 2021 (12.00),0
461,0.1,0.9,0.0,-0.2732,Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods,-1
462,0.0,0.894,0.106,0.4939,Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study.,1
463,0.0,1.0,0.0,0.0,Conjunctival epithelial cells resist productive SARS-CoV-2 infection,0
464,0.0,1.0,0.0,0.0,"SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties",0
465,0.0,1.0,0.0,0.0,"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial",0
466,0.0,0.807,0.193,0.6705,"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study",1
467,0.0,1.0,0.0,0.0,Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater,0
468,0.091,0.909,0.0,-0.0258,"Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, Spain",0
469,0.0,0.884,0.116,0.2732,Impact of Changes in Infection Control Measures on the Dynamics of COVID-19 Infections in Schools and Pre-schools,1
470,0.0,1.0,0.0,0.0,"Persistent symptoms among children and adolescents with and without anti-SARS-CoV-2 antibodies: a population-based serological study in Geneva, Switzerland",0
471,0.0,1.0,0.0,0.0,SARS-CoV-2 triggers complement activation through interactions with heparan sulfate,0
472,0.184,0.816,0.0,-0.4019,Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection,-1
473,0.314,0.686,0.0,-0.4939,COVID-19 reinfections among naturally infected and vaccinated individuals,-1
474,0.5,0.5,0.0,-0.6115,When viruses become more virulent,-1
475,0.0,1.0,0.0,0.0,"Estimating COVID-19 Infections, Hospitalizations, and Deaths After US Vaccination Campaigns",0
476,0.215,0.615,0.169,-0.1531,Association Between Immune Dysfunction and Breakthrough COVID-19 Infection After Vaccination,-1
477,0.0,1.0,0.0,0.0,Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection Summary: SARS CoV-2 S1 Protein in CD16+ Monocytes In PASC,0
478,0.0,1.0,0.0,0.0,Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529,0
479,0.0,0.827,0.173,0.3182,Rapid increase in Omicron infections in England during December 2021: REACT-1 study,1
480,0.0,1.0,0.0,0.0,Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant,0
481,0.0,1.0,0.0,0.0,The end of the pandemic will not be televised,0
482,0.0,1.0,0.0,0.0,Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19,0
483,0.0,1.0,0.0,0.0,"Long-term exposure to air pollution and COVID-19 incidence: a prospective study of residents in the city of Varese, Northern Italy",0
484,0.0,1.0,0.0,0.0,Omicron infection enhances neutralizing immunity against the Delta variant,0
485,0.0,0.842,0.158,0.128,Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies,1
486,0.0,1.0,0.0,0.0,Will Omicron end the pandemic? Here’s what experts say,0
487,0.0,1.0,0.0,0.0,A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase,0
488,0.0,1.0,0.0,0.0,The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic,0
489,0.0,0.675,0.325,0.6486,COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy,1
490,0.0,1.0,0.0,0.0,"One in ten people may still be infectious for COVID after ten days, new research indicates",0
491,0.0,1.0,0.0,0.0,Omicron in Scotland - Evidence Paper,0
492,0.0,1.0,0.0,0.0,Omicron severity: milder but not mild,0
493,0.135,0.865,0.0,-0.3612,Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2,-1
494,0.0,1.0,0.0,0.0,Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective,0
495,0.0,1.0,0.0,0.0,Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants,0
496,0.0,1.0,0.0,0.0,"Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial",0
497,0.0,1.0,0.0,0.0,Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19,0
498,0.204,0.796,0.0,-0.3182,Paper claiming a lack of evidence COVID-19 lockdowns work is retracted,-1
499,0.0,0.874,0.126,0.0772,Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant,0
500,0.0,0.814,0.186,0.4939,Feasibility of SARS-CoV-2 Surveillance Testing Among Children and Childcare Workers at German Day Care Centers,1
501,0.0,1.0,0.0,0.0,Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar,0
502,0.0,1.0,0.0,0.0,"Sildenafil for the Treatment of Patients With COVID-19 and Perfusion Mismatch on Subtraction Computed Tomography Angiography: A Pilot, Placebo-Controlled Randomised Trial",0
503,0.0,1.0,0.0,0.0,RECOVERY Trial to investigate sotrovimab as a possible treatment for hospitalised COVID-19 patients,0
504,0.21,0.618,0.172,-0.34,"Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform",-1
505,0.0,1.0,0.0,0.0,Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC),0
506,0.314,0.686,0.0,-0.4939,Influence of aluminum salts on COVID-19 infected patients,-1
507,0.0,0.871,0.129,0.3626,SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells,1
508,0.0,1.0,0.0,0.0,Patterns of Volatility Across the Spike Protein Accurately Predict the Emergence of Mutations within SARS-CoV-2 Lineages,0
509,0.0,1.0,0.0,0.0,Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals,0
510,0.0,1.0,0.0,0.0,UKHSA therapeutic technical briefing published,0
511,0.0,0.811,0.189,0.2732,The Dynamics of SARS-CoV-2 Infectivity with Changes in Aerosol Microenvironment,1
512,0.0,1.0,0.0,0.0,Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination,0
513,0.0,1.0,0.0,0.0,Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant,0
514,0.336,0.664,0.0,-0.8225,"Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation",-1
515,0.0,1.0,0.0,0.0,"Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine",0
516,0.0,1.0,0.0,0.0,Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies,0
517,0.0,1.0,0.0,0.0,Neutralization and Stability of SARS-CoV-2 Omicron Variant,0
518,0.0,0.699,0.301,0.5574,Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review,1
519,0.0,1.0,0.0,0.0,The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines,0
520,0.223,0.777,0.0,-0.3182,Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents,-1
521,0.0,1.0,0.0,0.0,COVID-19 wastewater surveillance implemented in the Tokyo 2020 Olympic and Paralympic Village,0
522,0.0,1.0,0.0,0.0,SARS-CoV-2 variants of concern and variants under investigation in England,0
523,0.0,1.0,0.0,0.0,"Protective effect of BNT162b2 vaccination on aerobic capacity following mild to moderate SARS-CoV-2 infection: a cross sectional study, Israel, March-December 2021",0
524,0.0,1.0,0.0,0.0,Coronavirus (COVID-19) and the use of face coverings in education settings,0
525,0.0,1.0,0.0,0.0,"Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity",0
526,0.0,0.892,0.108,0.1779,Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies,1
527,0.177,0.823,0.0,-0.4215,Endothelial dysfunction is the key of long COVID-19 symptoms: The results of TUN-EndCOV study,-1
528,0.133,0.867,0.0,-0.3818,How Does Severe Acute Respiratory Syndrome-Coronavirus-2 Affect the Brain and Its Implications for the Vaccines Currently in Use,-1
529,0.13,0.87,0.0,-0.2732,Anosmia and dysgeusia amongst COVID‐19 patients are associated with low levels of serum glucagon‐like peptide 1,-1
530,0.0,1.0,0.0,0.0,Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients,0
531,0.0,1.0,0.0,0.0,Predicting the mutational drivers of future SARS-CoV-2 variants of concern,0
532,0.212,0.788,0.0,-0.5423,Omicron cases are exploding. Scientists still don’t know how bad the wave will be,-1
533,0.0,0.837,0.163,0.5106,Strong SARS-CoV-2 N-specific CD8+ T immunity induced by engineered extracellular vesicles associates with protection from lethal infection in mice.,1
534,0.0,0.852,0.148,0.3818,Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection,1
535,0.0,1.0,0.0,0.0,T cell responses to SARS-CoV-2 spike cross-recognize Omicron,0
536,0.0,1.0,0.0,0.0,Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron,0
537,0.256,0.744,0.0,-0.4767,"High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh",-1
538,0.0,1.0,0.0,0.0,More infections in poorly ventilated classrooms,0
539,0.0,1.0,0.0,0.0,Long Covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19,0
540,0.0,0.847,0.153,0.4404,Rapid evidence review to inform safe return to campus in the context of coronavirus disease 2019 (COVID-19),1
541,0.0,1.0,0.0,0.0,Distinguishing COVID-19 infection and vaccination history by T cell reactivity,0
542,0.293,0.533,0.173,-0.4215,Recommendations to protect patients with cancer against the Omicron variant,-1
543,0.453,0.405,0.142,-0.6808,Concern about salient pathogen threats increases sensitivity to disgust,-1
544,0.189,0.811,0.0,-0.2732,Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK),-1
545,0.0,1.0,0.0,0.0,Functional Mobility Following COVID-19 in Adults 50 Years or Older in Canada,0
546,0.0,0.763,0.237,0.4215,Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients,1
547,0.0,0.769,0.231,0.5574,"Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001",1
548,0.167,0.833,0.0,-0.296,Plant-based diets or pescatarian diets associated with lower odds of moderate-to-severe COVID-19,-1
549,0.0,1.0,0.0,0.0,Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series,0
550,0.0,1.0,0.0,0.0,Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses,0
551,0.225,0.775,0.0,-0.4404,Burden of SARS-CoV-2 and protection from symptomatic second infection in children,-1
552,0.155,0.845,0.0,-0.296,Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review,-1
553,0.0,0.843,0.157,0.3818,Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose,1
554,0.237,0.763,0.0,-0.7096,Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2,-1
555,0.0,1.0,0.0,0.0,Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery,0
556,0.0,1.0,0.0,0.0,Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice,0
557,0.0,1.0,0.0,0.0,Screening for SARS-CoV-2 persistence in Long COVID patients using sniffer dogs and scents from axillary sweats samples,0
558,0.0,1.0,0.0,0.0,HKUMed reports that SARS-CoV-2 Omicron infection recalls mRNA-vaccine-induced immunity for broad protection,0
559,0.0,0.8,0.2,0.3612,Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant,1
560,0.0,1.0,0.0,0.0,Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern,0
561,0.0,1.0,0.0,0.0,Serological screening suggests single SARS-CoV-2 spillover events to cattle,0
562,0.0,1.0,0.0,0.0,"Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa",0
563,0.0,1.0,0.0,0.0,"Shorter serial intervals in SARS-CoV-2 cases with Omicron variant compared to Delta variant in the Netherlands, 13 – 19 December 2021",0
564,0.342,0.658,0.0,-0.3818,Severe COVID could reduce male fertility,-1
565,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - January 24, 2022",0
566,0.0,1.0,0.0,0.0,"Omicron, Its Mutations, and the Antibody Response",0
567,0.0,1.0,0.0,0.0,Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms,0
568,0.0,0.761,0.239,0.5267,Relative Instantaneous Reproduction Number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark,1
569,0.0,1.0,0.0,0.0,Coronavirus (COVID-19) Update: FDA Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Years of Age,0
570,0.113,0.655,0.232,0.25,Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses,1
571,0.0,0.896,0.104,0.296,"Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron",1
572,0.0,0.825,0.175,0.1779,Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization,1
573,0.0,1.0,0.0,0.0,mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARSCoV-2 Omicron variant,0
574,0.0,1.0,0.0,0.0,Waning of SARS-CoV-2 booster viral-load reduction effectiveness,0
575,0.0,1.0,0.0,0.0,Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa,0
576,0.0,1.0,0.0,0.0,Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2,0
577,0.0,0.769,0.231,0.5106,Relationship of SARS-CoV-2 Antigen and Reverse Transcription PCR Positivity for Viral Cultures,1
578,0.0,1.0,0.0,0.0,Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19,0
579,0.0,1.0,0.0,0.0,A human monoclonal antibody potently pan-neutralizes SARS-CoV-2 VOCs by targeting RBD invariant sites,0
580,0.138,0.64,0.222,0.1779,Analysis of receptors responsible for the dysfunction of the human immune system by different viral infections,1
581,0.0,1.0,0.0,0.0,Evidence of antibodies against SARS-CoV-2 in wild mustelids from Brittany (France),0
582,0.0,1.0,0.0,0.0,Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters,0
583,0.0,1.0,0.0,0.0,Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant,0
584,0.0,1.0,0.0,0.0,"Structure of the SARS-CoV-2 Nsp1/5′-Untranslated Region Complex and Implications for Potential Therapeutic Targets, a Vaccine, and Virulence",0
585,0.0,0.909,0.091,0.1027,Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds,1
586,0.0,0.72,0.28,0.5423,Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose,1
587,0.217,0.783,0.0,-0.3612,Disruption of nuclear architecture as a cause of COVID-19 induced anosmia,-1
588,0.0,1.0,0.0,0.0,SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons,0
589,0.0,1.0,0.0,0.0,"Omicron outbreak at a private gathering in the Faroe Islands, infecting 21 of 33 triple-vaccinated healthcare workers",0
590,0.0,1.0,0.0,0.0,Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2,0
591,0.0,1.0,0.0,0.0,Coronavirus can have been in Norway already in 2019,0
592,0.0,1.0,0.0,0.0,SARS-CoV-2 Omicron and Delta variants conserve epitopes present in Abdala and Soberana Cuban anti-covid-19 vaccines,0
593,0.0,1.0,0.0,0.0,"Prevalence, characteristics, and predictors of Long COVID among diagnosed cases of COVID-19",0
594,0.0,1.0,0.0,0.0,Serological Markers of SARS-CoV-2 Reinfection,0
595,0.0,0.667,0.333,0.25,COVID-19: endemic doesn’t mean harmless,1
596,0.268,0.732,0.0,-0.5267,"Associations between adverse childhood experiences, attitudes towards COVID-19 restrictions and vaccine hesitancy: a cross-sectional study",-1
597,0.0,0.755,0.245,0.3818,Context-specific emergence and growth of the SARS-CoV-2 Delta variant,1
598,0.271,0.729,0.0,-0.3818,High-Dose Convalescent Plasma for Treatment of Severe COVID-19,-1
599,0.0,1.0,0.0,0.0,"Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil",0
600,0.0,0.909,0.091,0.34,"Antibody-mediated Immunogenicity against SARS-CoV-2 following priming, boosting and hybrid immunity: insights from 11 months of follow-up of a healthcare worker cohort in Israel, December 2020-October 2021",1
601,0.0,1.0,0.0,0.0,mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant,0
602,0.0,1.0,0.0,0.0,"Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany",0
603,0.0,1.0,0.0,0.0,Determining quarantine length and testing frequency for international border opening during the COVID-19 pandemic,0
604,0.0,1.0,0.0,0.0,Where did Omicron come from? Three key theories,0
605,0.0,1.0,0.0,0.0,Multisystem Involvement in Post‐Acute Sequelae of Coronavirus Disease 19,0
606,0.0,1.0,0.0,0.0,Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study,0
607,0.0,1.0,0.0,0.0,COVID-19 vaccine surveillance report Week 4,0
608,0.115,0.885,0.0,-0.0772,High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor,0
609,0.0,1.0,0.0,0.0,SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 31 - 10 December 2021,0
610,0.0,1.0,0.0,0.0,Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants,0
611,0.0,1.0,0.0,0.0,Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19,0
612,0.0,1.0,0.0,0.0,"The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients",0
613,0.188,0.647,0.165,-0.1027,Efficient mucosal antibody response to SARS-CoV-2 vaccination is induced in previously infected individuals,-1
614,0.0,0.888,0.112,0.34,Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine,1
615,0.0,1.0,0.0,0.0,"SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia",0
616,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - January 17, 2022",0
617,0.0,0.733,0.267,0.4588,"CDC Recommends Pfizer Booster at 5 Months, Additional Primary Dose for Certain Immunocompromised Children",1
618,0.0,0.889,0.111,0.128,An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies,1
619,0.037,0.892,0.071,0.2732,Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants,1
620,0.0,1.0,0.0,0.0,Emerging spectrum of post-COVID-19 syndrome,0
621,0.0,1.0,0.0,0.0,Discovering Paxlovid,0
622,0.355,0.645,0.0,-0.6597,COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer,-1
623,0.0,1.0,0.0,0.0,Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study,0
624,0.0,0.902,0.098,0.0772,Challenges in inferring intrinsic severity of SARS-CoV-2 Omicron variant from early population-level impact,0
625,0.0,1.0,0.0,0.0,ESCPE-1 Mediates Retrograde Endosomal Sorting of the SARS-CoV-2 Host Factor Neuropilin-1,0
626,0.0,1.0,0.0,0.0,Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset,0
627,0.0,1.0,0.0,0.0,SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation,0
628,0.0,0.777,0.223,0.3182,SARS-CoV-2 Vaccination boosts Neutralizing Activity against Seasonal Human Coronaviruses,1
629,0.0,1.0,0.0,0.0,"Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.",0
630,0.0,0.839,0.161,0.3182,FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19,1
631,0.0,1.0,0.0,0.0,Psychological Predictors of Self-reported COVID-19 Outcomes: Results From a Prospective Cohort Study,0
632,0.0,0.861,0.139,0.2732,Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission,1
633,0.0,0.795,0.205,0.2023,Covid-19: An urgent call for global “vaccines-plus” action,1
634,0.0,1.0,0.0,0.0,N95 vs Half-face Respirator Wear in Surgical Trainees: Physiologic and Psychological Effects of Prolonged Use,0
635,0.0,0.792,0.208,0.6705,"Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial",1
636,0.0,0.595,0.405,0.7579,Reduced infectivity but increased immune escape of the new SARS-CoV-2 variant of concern Omicron,1
637,0.167,0.833,0.0,-0.25,High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain,-1
638,0.0,1.0,0.0,0.0,Protection against Covid-19 by BNT162b2 Booster across Age Groups,0
639,0.0,1.0,0.0,0.0,Pulse oximeters’ measurements vary across ethnic groups: An observational study in patients with Covid-19 infection,0
640,0.0,1.0,0.0,0.0,Effect of BCG vaccination against SARS-CoV-2 infection,0
641,0.0,1.0,0.0,0.0,Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection,0
642,0.0,1.0,0.0,0.0,"SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020–March 2021",0
643,0.0,1.0,0.0,0.0,Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France,0
644,0.167,0.833,0.0,-0.3818,Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19.,-1
645,0.0,1.0,0.0,0.0,The Omicron Variant Increases the Interactions of SARS-CoV-2 Spike Glycoprotein with ACE2,0
646,0.0,1.0,0.0,0.0,Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients,0
647,0.0,1.0,0.0,0.0,Mapping the allosteric effects that define functional activity of SARS-CoV-2 specific antibodies,0
648,0.0,1.0,0.0,0.0,Local and systemic responses to SARS-CoV-2 infection in children and adults,0
649,0.259,0.741,0.0,-0.2732,COVID vaccination and age-stratified all-cause mortality risk,-1
650,0.0,0.811,0.189,0.4215,Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03,1
651,0.0,0.871,0.129,0.4767,Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations,1
652,0.044,0.813,0.143,0.6845,"The US government has launched an official website that will offer free COVID-19 tests to US homes. Starting next Wed, Jan 19th, every home in the U.S. can order 4 free at-⁠home COVID-⁠19 tests. The tests will be completely free—there are no shipping costs. (This is a direct link to the website)",1
653,0.173,0.827,0.0,-0.3182,CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation,-1
654,0.0,1.0,0.0,0.0,"Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa",0
655,0.195,0.651,0.153,-0.3182,Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death,-1
656,0.0,1.0,0.0,0.0,Cerebrospinal Fluid Offers Clues to Post-COVID ‘Brain Fog’,0
657,0.0,1.0,0.0,0.0,Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies,0
658,0.0,0.872,0.128,0.4215,"Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August 2021",1
659,0.0,1.0,0.0,0.0,Omicron is a Multiply Recombinant Set of Variants That Have Evolved Over Many Months,0
660,0.0,0.606,0.394,0.6369,Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement,1
661,0.0,0.766,0.234,0.6369,Improved binding affinity of the Omicron's spike protein with hACE2 receptor is the key factor behind its increased virulence,1
662,0.0,1.0,0.0,0.0,Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital,0
663,0.0,0.875,0.125,0.25,QTQTN motif upstream of the furin-cleavage site plays key role in SARS-CoV-2 infection and pathogenesis.,1
664,0.234,0.567,0.199,-0.128,Lung Transplantation for Covid-19–Related Respiratory Failure in the United States,-1
665,0.0,1.0,0.0,0.0,Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age,0
666,0.237,0.763,0.0,-0.4215,Executive dysfunction following SARS-CoV-2 infection: A cross-sectional examination in a population-representative sample,-1
667,0.0,0.761,0.239,0.296,Evolution of enhanced innate immune evasion by SARS-CoV-2,1
668,0.0,1.0,0.0,0.0,Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection,0
669,0.0,1.0,0.0,0.0,Impact of SARS-CoV-2 variants on inpatient clinical outcome,0
670,0.0,0.656,0.344,0.2732,SARS-CoV-2 Aerosol Dynamics: a consensus statement,1
671,0.0,1.0,0.0,0.0,Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave,0
672,0.0,1.0,0.0,0.0,Supervised and Self-supervised Pretraining Based COVID-19 Detection Using Acoustic Breathing/Cough/Speech Signals,0
673,0.0,1.0,0.0,0.0,Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts,0
674,0.0,0.806,0.194,0.5574,Neurodevelopmental outcomes at one year in offspring of mothers who test positive for SARS-CoV-2 during pregnancy,1
675,0.157,0.843,0.0,-0.4215,Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction,-1
676,0.383,0.5,0.117,-0.5859,Immunocompromised children and young people are at no increased risk of severe COVID-19,-1
677,0.0,1.0,0.0,0.0,Weekly Epidemiological Brief,0
678,0.0,1.0,0.0,0.0,End-to-end system for rapid and sensitive early-detection of SARS-CoV-2 for resource-poor and field-test environments using a $51 lab-in-a-backpack,0
679,0.0,0.741,0.259,0.4215,"Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021",1
680,0.0,1.0,0.0,0.0,Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review,0
681,0.0,1.0,0.0,0.0,Emergence of within-host SARS-CoV-2 recombinant genome after coinfection by Gamma and Delta variants,0
682,0.0,1.0,0.0,0.0,COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins,0
683,0.0,1.0,0.0,0.0,Binding of phosphatidylserine‐positive microparticles by PBMCs classifies disease severity in COVID‐19 patients,0
684,0.075,0.925,0.0,-0.2732,Infection and transmission risks in schools and contribution to the COVID-19 pandemic in Germany – a retrospective observational study using nation-wide and regional health and education agency notification data,-1
685,0.0,1.0,0.0,0.0,"Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show",0
686,0.0,1.0,0.0,0.0,Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant,0
687,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - December 13, 2021",0
688,0.0,1.0,0.0,0.0,Covid-19 Vaccine Effectiveness in New York State,0
689,0.0,1.0,0.0,0.0,Post-COVID-19 Memory Impairment: Prevalence and Associated Factors,0
690,0.0,1.0,0.0,0.0,Acute COVID-19 severity and 16-month mental morbidity trajectories in patient populations of six nations,0
691,0.0,1.0,0.0,0.0,Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme,0
692,0.0,1.0,0.0,0.0,Plasma neutralization properties of the SARS-CoV-2 Omicron variant,0
693,0.0,1.0,0.0,0.0,The effect of eye protection on SARS-CoV-2 transmission: a systematic review,0
694,0.0,1.0,0.0,0.0,Neutralizing antibody-independent SARS-CoV-2 control correlated with intranasal vaccine-induced CD8+ T-cell responses,0
695,0.0,1.0,0.0,0.0,Deltacron: the story of the variant that wasn’t,0
696,0.0,1.0,0.0,0.0,Transmission of SARS-CoV-2 from humans to animals and potential host adaptation,0
697,0.0,0.719,0.281,0.4404,Immune escape of SARS-CoV-2 Omicron variant from mRNA vaccination-elicited RBD-specific memory B cells.,1
698,0.0,1.0,0.0,0.0,SARS-CoV-2 Infection and Lung Regeneration,0
699,0.253,0.747,0.0,-0.5267,Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 Infection,-1
700,0.0,1.0,0.0,0.0,"Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study",0
701,0.0,0.855,0.145,0.1779,Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies,1
702,0.0,0.864,0.136,0.4588,"Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries",1
703,0.0,1.0,0.0,0.0,An Overview About the Role of Adaptive Immunity in Keeping SARS-CoV-2 Reinfections at Bay,0
704,0.0,1.0,0.0,0.0,"Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers",0
705,0.0,1.0,0.0,0.0,3D virtual histopathology of cardiac tissue from Covid-19 patients based on phase-contrast X-ray tomography,0
706,0.0,1.0,0.0,0.0,Genomic determinants of Furin cleavage in diverse European SARS-related bat coronaviruses,0
707,0.0,0.667,0.333,0.6705,Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting,1
708,0.0,1.0,0.0,0.0,Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households,0
709,0.462,0.538,0.0,-0.7184,baseline metabolic profiling and risk of death from covid-19,-1
710,0.0,0.901,0.099,0.0258,Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis,0
711,0.0,1.0,0.0,0.0,Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor binding domain,0
712,0.144,0.673,0.183,0.3182,"Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021",1
713,0.174,0.826,0.0,-0.2732,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,-1
714,0.0,1.0,0.0,0.0,Factors associated with excess all-cause mortality in the first wave of the COVID-19 pandemic in the UK: A time series analysis using the Clinical Practice Research Datalink,0
715,0.0,1.0,0.0,0.0,Track Omicron’s spread with molecular data,0
716,0.0,0.606,0.394,0.6369,Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies,1
717,0.097,0.903,0.0,-0.128,The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2,-1
718,0.108,0.892,0.0,-0.3182,SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders,-1
719,0.0,1.0,0.0,0.0,Topological data analysis identifies distinct biomarker phenotypes during the inflammatory phase of COVID-19,0
720,0.0,1.0,0.0,0.0,Spatial epidemiology and genetic diversity of SARS-CoV-2 and related coronaviruses in domestic and wild animals,0
721,0.0,1.0,0.0,0.0,Incidence rates and symptomatology of community infections with SARS-CoV-2 in children and parents: The CoKids longitudinal household study,0
722,0.115,0.885,0.0,-0.5994,"COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021",-1
723,0.0,1.0,0.0,0.0,"COVID-19 trends and severity among symptomatic children aged 0–17 years in 10 European Union countries, 3 August 2020 to 3 October 2021",0
724,0.0,1.0,0.0,0.0,Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection,0
725,0.0,1.0,0.0,0.0,Neutralizing Antibody Activity Against SARS-CoV-2 Variants in Gestational Age-Matched Mother-Infant Dyads,0
726,0.0,0.851,0.149,0.5423,Superior immunity that allows neutralization of all SARS-CoV-2 variants of concern develops in COVID-19 convalescents and naïve individuals after three vaccinations,1
727,0.0,1.0,0.0,0.0,SARS-CoV-2 in domestic cats (Felis catus) in the northwest of Iran: Evidence for SARS-CoV-2 circulating between human and cats,0
728,0.0,1.0,0.0,0.0,Effectiveness of COVID-19 vaccines against Omicron or Delta infection,0
729,0.0,1.0,0.0,0.0,Three-dose vaccination elicits neutralising antibodies against omicron,0
730,0.0,0.909,0.091,0.0772,The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries,0
731,0.231,0.769,0.0,-0.2732,Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome,-1
732,0.0,1.0,0.0,0.0,VITT and Second Doses of Covid-19 Vaccine,0
733,0.0,1.0,0.0,0.0,The twin-beginnings of COVID-19 in Asia and Europe – One prevails quickly,0
734,0.0,1.0,0.0,0.0,Neutralising monoclonal antibody and intravenous antiviral treatments for patients in hospital with COVID-19 infection,0
735,0.22,0.593,0.186,-0.1027,Role of the T cell vitamin D receptor in severe COVID-19,-1
736,0.231,0.769,0.0,-0.2732,Risk of Cardiovascular Events after Covid-19: a double-cohort study,-1
737,0.0,1.0,0.0,0.0,Necessity of COVID-19 Vaccination in Persons Who Have Already Had COVID-19,0
738,0.0,0.878,0.122,0.2023,Development and Application of a Polydimethylsiloxane-Based Passive Air Sampler to Assess Personal Exposure to SARS-CoV-2,1
739,0.0,1.0,0.0,0.0,Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants,0
740,0.131,0.754,0.116,-0.0772,Texas Children’s Hospital and Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization in India,0
741,0.0,1.0,0.0,0.0,SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection,0
742,0.0,1.0,0.0,0.0,"Morphological, cellular and molecular basis of brain infection in COVID-19 patients",0
743,0.0,1.0,0.0,0.0,Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children,0
744,0.314,0.686,0.0,-0.296,Intranasal inhibitor blocks omicron and other variants of SARS-CoV-2,-1
745,0.126,0.874,0.0,-0.3818,SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease,-1
746,0.0,0.84,0.16,0.2732,"Serial Interval and Transmission Dynamics during SARS-CoV-2 Delta Variant Predominance, South Korea",1
747,0.0,1.0,0.0,0.0,In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness,0
748,0.0,0.821,0.179,0.34,Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses,1
749,0.149,0.851,0.0,-0.4215,CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population,-1
750,0.0,1.0,0.0,0.0,"Guillain-Barré Five Times More Likely in Unvaccinated, COVID-19-Positive Patients Than COVID-Vaccinated Patients",0
751,0.0,1.0,0.0,0.0,Plasma Neutralization of the SARS-CoV-2 Omicron Variant,0
752,0.167,0.833,0.0,-0.3818,HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses,-1
753,0.0,1.0,0.0,0.0,A literature review and meta-analysis of the effects of lockdowns on covid-19 mortality,0
754,0.503,0.497,0.0,-0.7968,Omicron's feeble attack on the lungs could make it less dangerous,-1
755,0.0,1.0,0.0,0.0,Β-Amyloid Deposits in Young COVID Patients,0
756,0.0,1.0,0.0,0.0,Antibody Responses to 3rd Dose mRNA Vaccines in Nursing Home and Assisted Living Residents,0
757,0.0,1.0,0.0,0.0,Evidence for a mouse origin of the SARS-CoV-2 Omicron variant,0
758,0.0,1.0,0.0,0.0,SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron,0
759,0.0,1.0,0.0,0.0,Capturing intrahost recombination of SARS-CoV-2 during superinfection with Alpha and Epsilon variants in New York City,0
760,0.0,1.0,0.0,0.0,"Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial",0
761,0.172,0.828,0.0,-0.4019,"Airborne Transmission of SARS-CoV-2 Delta Variant within Tightly Monitored Isolation Facility, New Zealand (Aotearoa)",-1
762,0.318,0.682,0.0,-0.4215,Mitochondrial Dysfunction: A Prelude to Neuropathogenesis of SARS-CoV-2,-1
763,0.0,0.69,0.31,0.3818,An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challenge,1
764,0.0,1.0,0.0,0.0,Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.,0
765,0.0,1.0,0.0,0.0,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",0
766,0.0,1.0,0.0,0.0,"SARS-CoV-2 Circulation, Guinea, March 2020–July 2021",0
767,0.0,1.0,0.0,0.0,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,0
768,0.0,1.0,0.0,0.0,Transmissibility of SARS-CoV-2 among fully vaccinated individuals,0
769,0.108,0.769,0.123,0.0772,Practical Indicators for Risk of Airborne Transmission in Shared Indoor Environments and Their Application to COVID-19 Outbreaks,0
770,0.172,0.591,0.237,0.0516,Chaotic dynamics in a novel COVID-19 pandemic model described by commensurate and incommensurate fractional-order derivatives,0
771,0.0,0.806,0.194,0.34,SARS-CoV-2 T cell responses are expected to remain robust against Omicron variant,1
772,0.0,1.0,0.0,0.0,"Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia",0
773,0.108,0.588,0.304,0.4588,How effective is a mask in preventing COVID‐19 infection?,1
774,0.126,0.874,0.0,-0.3818,Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine,-1
775,0.0,0.717,0.283,0.7269,Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant,1
776,0.0,1.0,0.0,0.0,Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine,0
777,0.0,0.857,0.143,0.3612,Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine,1
778,0.0,1.0,0.0,0.0,Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar,0
779,0.0,1.0,0.0,0.0,"A National Strategy for COVID-19 Testing, Surveillance, and Mitigation Strategies",0
780,0.0,0.899,0.101,0.4215,"Reported Cases of Multisystem Inflammatory Syndrome in Children Aged 12 to 20 Years in the United States Who Received COVID-19 Vaccine, December 2020 through August 2021",1
781,0.0,1.0,0.0,0.0,"Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies",0
782,0.0,0.902,0.098,0.34,Antibody response to SARS-CoV-2 for more than one year − kinetics and persistence of detection are predominantly determined by avidity progression and test design,1
783,0.0,1.0,0.0,0.0,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by Omicron and Delta Variants,0
784,0.0,0.725,0.275,0.4215,Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures,1
785,0.206,0.794,0.0,-0.3818,Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines,-1
786,0.0,1.0,0.0,0.0,Mechanisms of action of fluvoxamine for COVID-19: a historical review,0
787,0.0,0.897,0.103,0.1531,Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response,1
788,0.167,0.833,0.0,-0.296,No infectious SARS-CoV-2 in breast milk from a cohort of 110 lactating women,-1
789,0.0,0.763,0.237,0.4215,Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study,1
790,0.0,1.0,0.0,0.0,Fluvastatin mitigates SARS-CoV-2 infection in human lung cells,0
791,0.0,0.513,0.487,0.5719,The significant immune escape of pseudotyped SARS-CoV-2 Variant Omicron,1
792,0.312,0.346,0.342,0.1779,Tonnes of COVID-19 health care waste expose urgent need to improve waste management systems,1
793,0.0,0.879,0.121,0.296,Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease,1
794,0.421,0.579,0.0,-0.6249,Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2,-1
795,0.0,1.0,0.0,0.0,Asthma Flares after Vaccination,0
796,0.163,0.837,0.0,-0.5719,"Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against COVID-19 related symptoms and hospitalisation in England: test negative case-control study",-1
797,0.0,1.0,0.0,0.0,Control and Prevention of the COVID-19 Epidemic in China: A Qualitative Community Case Study,0
798,0.0,0.774,0.226,0.4215,Identifying protein sites contributing to vaccine escape via statistical comparisons of short-term molecular dynamics simulations,1
799,0.0,1.0,0.0,0.0,SARS-CoV-2 variants of concern and variants under investigation in England - Technical briefing 33,0
800,0.0,0.914,0.086,0.1779,Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time,1
801,0.0,1.0,0.0,0.0,Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues,0
802,0.0,0.87,0.13,0.128,B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes,1
803,0.0,1.0,0.0,0.0,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,0
804,0.0,1.0,0.0,0.0,COVID-19 Data Briefing (21 December 2021),0
805,0.0,1.0,0.0,0.0,Persistent SARS-CoV-2 Infection with Accumulation of Mutations in a Patient with Poorly Controlled HIV Infection,0
806,0.189,0.811,0.0,-0.2732,Risk factor targeting for vaccine prioritization during the COVID-19 pandemic,-1
807,0.0,1.0,0.0,0.0,Extreme γ' fibrinogen levels in COVID-19 patients,0
808,0.0,0.645,0.355,0.6705,South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine,1
809,0.172,0.828,0.0,-0.3612,Non-cell autonomous disruption of nuclear architecture as a potential cause of COVID-19 induced anosmia,-1
810,0.189,0.811,0.0,-0.2732,Modelling the direct virus exposure risk associated with respiratory events,-1
811,0.0,1.0,0.0,0.0,Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants,0
812,0.0,1.0,0.0,0.0,Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera,0
813,0.0,1.0,0.0,0.0,Brain perfusion single-photon emission computerized tomography/computerized tomography: Stroke-like manifestations of COVID-19 with transient antiphospholipid elevation,0
814,0.0,1.0,0.0,0.0,The COVID generation: how is the pandemic affecting kids’ brains?,0
815,0.0,0.855,0.145,0.296,Structural and functional characterizations of altered infectivity and immune evasion of SARS-CoV-2 Omicron variant,1
816,0.162,0.689,0.15,-0.1027,"The good, the bad, and the neutral: Vaccine hesitancy mediates the relations of Psychological Capital, the Dark Triad, and the Big Five with vaccination willingness and behaviors",-1
817,0.0,1.0,0.0,0.0,A sarbecovirus found in Russian bats uses human ACE2,0
818,0.0,0.885,0.115,0.0772,"Three, four or more: what’s the magic number for booster shots?",0
819,0.0,1.0,0.0,0.0,Mapping SARS-CoV-2 antigenic relationships and serological responses,0
820,0.259,0.741,0.0,-0.5994,Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates,-1
821,0.0,1.0,0.0,0.0,Longitudinal Assessment of Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children Associated With COVID‐19 Infections,0
822,0.0,1.0,0.0,0.0,Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection,0
823,0.0,1.0,0.0,0.0,"Comparison of Complications after Coronavirus Disease and Seasonal Influenza, South Korea",0
824,0.132,0.868,0.0,-0.4939,Blood Markers of Brain Damage Are Higher Over Short Term in Patients Who Have COVID-19 Than in People Who Have Alzheimer’s Disease,-1
825,0.0,1.0,0.0,0.0,Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection,0
826,0.0,1.0,0.0,0.0,Analysis: A meta-analysis of Early Results to predict Vaccine efficacy against Omicron,0
827,0.0,1.0,0.0,0.0,"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines",0
828,0.0,1.0,0.0,0.0,Association of Child Masking With COVID-19 Childcare Program Closures,0
829,0.0,1.0,0.0,0.0,Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac Injuries,0
830,0.0,1.0,0.0,0.0,Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection,0
831,0.0,1.0,0.0,0.0,Face masks reduce emotion-recognition accuracy and perceived closeness,0
832,0.0,1.0,0.0,0.0,Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron (B.1.1.529),0
833,0.0,0.694,0.306,0.296,The T cell immune response against SARS-CoV-2,1
834,0.0,1.0,0.0,0.0,Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection,0
835,0.0,1.0,0.0,0.0,mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant,0
836,0.321,0.597,0.082,-0.7506,Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction,-1
837,0.0,1.0,0.0,0.0,Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function,0
838,0.0,1.0,0.0,0.0,SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34,0
839,0.0,1.0,0.0,0.0,Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19,0
840,0.0,1.0,0.0,0.0,Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant,0
841,0.0,1.0,0.0,0.0,SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland,0
842,0.0,1.0,0.0,0.0,"Formal meeting (oral evidence session): UK Science, Research and Technology Capability and Influence in Global Disease Outbreaks",0
843,0.0,1.0,0.0,0.0,"The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta Variants: a computational approach",0
844,0.0,1.0,0.0,0.0,"Weekly Scientific Discussion Thread - January 31, 2022",0
845,0.0,1.0,0.0,0.0,Clinical Outcomes Among Hospitalized Youths With COVID-19 in Sub-Saharan Africa,0
846,0.239,0.761,0.0,-0.296,Deaths from COVID-19 with no other underlying causes,-1
847,0.0,1.0,0.0,0.0,Breakthrough infections with SARS-CoV-2 Omicron variant despite booster dose of mRNA vaccine,0
848,0.0,0.902,0.098,0.0772,Serial interval and basic reproduction number of SARS-CoV-2 Omicron variant in South Korea,0
849,0.0,1.0,0.0,0.0,Homologous and Heterologous Covid-19 Booster Vaccinations,0
850,0.0,0.769,0.231,0.4019,Optimising predictive models to prioritise viral discovery in zoonotic reservoirs,1
851,0.0,1.0,0.0,0.0,Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant,0
852,0.0,1.0,0.0,0.0,Fluvoxamine for outpatients with COVID-19: where do we stand?,0
853,0.0,1.0,0.0,0.0,Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2 infection and SARS-CoV-2 Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium,0
854,0.0,1.0,0.0,0.0,Metabolic associated fatty liver disease is highly prevalent in the post-acute COVID syndrome,0
855,0.0,1.0,0.0,0.0,Preferential expansion of cross-reactive pre-existing switched memory B cells that recognize the SARS-CoV-2 Omicron variant Spike protein,0
856,0.196,0.804,0.0,-0.5994,"Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period",-1
857,0.046,0.837,0.117,0.4019,"Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021",1
858,0.0,1.0,0.0,0.0,"Design and Implementation Of ICE-COVID, A Double-Blind Randomised Placebo-Controlled Trial on The Efficacy of Iota-Carrageenan Nasal and Throat Spray for Covid-19 Prophylaxis",0
859,0.131,0.754,0.116,-0.0772,Texas Children’s Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India,0
860,0.0,0.889,0.111,0.25,Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons,1
861,0.164,0.756,0.08,-0.4404,Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection,-1
862,0.082,0.863,0.055,-0.1779,European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression,-1
863,0.0,0.855,0.145,0.296,Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells,1
864,0.275,0.625,0.1,-0.5859,Humoral Responses after SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients,-1
865,0.0,1.0,0.0,0.0,SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients.,0
866,0.0,0.864,0.136,0.296,Immune system cells from COVID-19 patients display compromised mitochondrial-nuclear expression co-regulation and rewiring toward glycolysis,1
867,0.102,0.898,0.0,-0.1779,Anxiety and harmful oral habits in preschool children during the 2020 first-wave COVID‑19 lockdown in Turkey,-1
868,0.0,1.0,0.0,0.0,Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles,0
869,0.157,0.843,0.0,-0.4215,Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study,-1
870,0.0,1.0,0.0,0.0,Characterisation of COVID-19 deaths by vaccination types and status in Malaysia between February and September 2021,0
871,0.0,0.845,0.155,0.296,The Female Predominant Persistent Immune Dysregulation of the Post COVID Syndrome: A Cohort Study,1
872,0.0,1.0,0.0,0.0,Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater,0
873,0.0,1.0,0.0,0.0,Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant,0
874,0.0,1.0,0.0,0.0,Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants,0
875,0.0,1.0,0.0,0.0,"SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses",0
876,0.0,1.0,0.0,0.0,Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals.,0
877,0.222,0.684,0.094,-0.3612,Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients,-1
878,0.0,1.0,0.0,0.0,A humanized mouse model of chronic COVID-19,0
879,0.149,0.851,0.0,-0.2732,Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19,-1
880,0.0,0.839,0.161,0.3182,The Promise of Disease Detection Dogs in Pandemic Response: Lessons Learned From COVID-19,1
881,0.0,1.0,0.0,0.0,Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants,0
882,0.0,1.0,0.0,0.0,Beyond Omicron: what’s next for COVID’s viral evolution,0
883,0.0,1.0,0.0,0.0,"Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants",0
884,0.0,1.0,0.0,0.0,Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations,0
885,0.0,0.884,0.116,0.2732,"The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, transmissibility, and fitness in the golden Syrian hamster model",1
886,0.15,0.85,0.0,-0.5719,Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland,-1
887,0.0,1.0,0.0,0.0,"Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada",0
888,0.0,0.687,0.313,0.4767,Omicron favors neuropilin1 binding over ACE2: Increased infectivity and available drugs,1
889,0.123,0.877,0.0,-0.2732,Myocarditis Risk 17 Times Higher for Unvaccinated Patients Ages 12-30 Who Get COVID-19 Than COVID-Vaccinated Patients,-1
890,0.147,0.853,0.0,-0.2263,Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination,-1
891,0.0,1.0,0.0,0.0,COVID-19 targets human adrenal glands,0
892,0.0,0.769,0.231,0.34,Robust and durable serological response following pediatric SARS-CoV-2 infection,1
893,0.0,1.0,0.0,0.0,mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship,0
894,0.0,0.581,0.419,0.6705,"Report 49 - Growth, population distribution and immune escape of Omicron in England",1
895,0.0,1.0,0.0,0.0,In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus Disease 2019 (COVID-19) Vaccination,0
896,0.0,1.0,0.0,0.0,Antivirals and neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients,0
897,0.0,1.0,0.0,0.0,Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths,0
898,0.0,0.887,0.113,0.4939,"Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa",1
899,0.119,0.881,0.0,-0.3182,Effects of Weight Loss on Adipose and Muscular Neuropilin 1 mRNA Expression in Obesity: Potential Implication in SARS-CoV-2 Infections?,-1
900,0.0,1.0,0.0,0.0,"Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy",0
901,0.0,0.889,0.111,0.128,Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses,1
902,0.0,1.0,0.0,0.0,"Compared with SARS-CoV2 wild type’s spike protein, the SARS-CoV2 omicron’s receptor binding motif has adopted a more SARS-CoV1 and/or bat/civet-like structure",0
903,0.0,1.0,0.0,0.0,T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals,0
904,0.116,0.884,0.0,-0.3612,"Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study",-1
905,0.0,1.0,0.0,0.0,Pfizer's Paxlovid Holds Up,0
906,0.084,0.803,0.112,0.1779,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years — United States, March 1, 2020–June 28, 2021",1
907,0.0,1.0,0.0,0.0,It’s not too late,0
908,0.0,1.0,0.0,0.0,Covid-19: Whatever happened to the Novavax vaccine?,0
909,0.076,0.924,0.0,-0.1027,SARS-CoV-2 entry sites are present in all structural elements of the human glossopharyngeal and vagal nerves: clinical implications,-1
910,0.0,0.866,0.134,0.1779,"Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020–2021",1
911,0.0,1.0,0.0,0.0,Prevalence and Durability of SARS-COV-2 Antibodies Among Unvaccinated US Adults By History Of Covid-19,0
912,0.0,0.714,0.286,0.4215,"Oral COVID-19 antiviral, Paxlovid, approved by UK regulator",1
913,0.0,0.732,0.268,0.296,Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion,1
914,0.0,1.0,0.0,0.0,"SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March–June 2021",0
915,0.0,1.0,0.0,0.0,SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology,0
916,0.0,1.0,0.0,0.0,"Prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility",0
917,0.0,1.0,0.0,0.0,Multi-organ assessment in mainly nonhospitalized individuals after SARS-CoV-2 infection. The Hamburg City Health Study COVID programme,0
918,0.0,0.878,0.122,0.4939,"Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial",1
919,0.0,1.0,0.0,0.0,SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals,0
920,0.0,1.0,0.0,0.0,"Broadly-recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles",0
921,0.245,0.755,0.0,-0.3818,Complement activation induces excessive T cell cytotoxicity in severe COVID-19,-1
922,0.0,1.0,0.0,0.0,Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19,0
923,0.0,0.876,0.124,0.34,Report 48 - The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant,1
924,0.0,1.0,0.0,0.0,The Goldilocks Time for Remdesivir — Is Any Indication Just Right?,0
925,0.0,1.0,0.0,0.0,Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study,0
926,0.0,0.859,0.141,0.4215,Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial,1
927,0.0,1.0,0.0,0.0,Structural basis of Omicron neutralization by affinity-matured public antibodies,0
928,0.097,0.903,0.0,-0.4019,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study",-1
929,0.122,0.878,0.0,-0.4939,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021,-1
930,0.0,1.0,0.0,0.0,Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation,0
931,0.0,1.0,0.0,0.0,Acute SARS-CoV-2 infection in pregnancy is associated with placental ACE2 shedding.,0
